Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies.doi:10.1007/s10637-018-0615-8Sarshekeh, Amir Mehrvarz...